drugset
drugset / Trial / NCT03867253

Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease

NCT03867253 ↗

Phase 2 Completed 24 enrolled Oryzon Genomics S.A. Alzheimer's Drug Discovery Foundation · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase IIa study assessing the safety, tolerability and preliminary efficacy of ORY-2001 in mild to moderate Alzheimer's Disease patients.

Timeline

Start
2019-05-16
Primary completion
2020-11-12
Completion
2020-11-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator vafidemstat Small molecule 0.6 mg —
Comparator vafidemstat Small molecule 1.2 mg —

Indications

No indication recorded.